Kelly CRISPR & Gene Editing Technology ETF
XDNA
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 7887 East Belleview Avenue, Suite 1100 Englewood CO Canada 80111
- IPO Date
- Jan 13, 2022
- CIK
- 0001873280
- Similar Companies
- Business
- Kelly CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that tracks the Strategic CRISPR & Gene Editing Technology Index, providing investors with exposure to companies in developed markets focused on advancements in DNA modification technology. The ETF offers a passively managed, concentrated portfolio targeting three sub-sectors: CRISPR & gene editing technology for applications in biological research, biotechnological products, and disease treatment; gene editing development solutions involving therapeutic product rights and intellectual property; and gene editing sequencing solutions for analyzing edited gene functions. It invests primarily in equities of firms operating across healthcare, pharmaceuticals, biotechnology, and life sciences, with a market-cap-weighted approach emphasizing growth and value stocks of varying market capitalizations; geographic operations span the US and other developed markets globally. Launched on January 12, 2022, and listed on Nasdaq, XDNA is issued by Kelly Strategic Management, LLC (formerly associated with Kelly ETFs), with Dustin Lewellyn, Ernesto Tong, and Anand Desai serving as fund managers. The fund maintains a net expense ratio of 0.78%, with assets under management at approximately $2.58 million and around 26 holdings as of recent data, though top holdings may include cash equivalents amid low trading volume. Kelly Strategic Management, headquartered in Denver, Colorado, positions the ETF as a cost-effective, diversified tool for thematic exposure to genomic innovation, complementing traditional healthcare strategies with low index overlap. In recent developments, XDNA has experienced significant operational challenges, including low assets leading to limited liquidity and average daily volume near zero; the fund underwent a creation re-opening as announced in a press release, signaling efforts to attract new shares amid market pressures. As of late 2023, reports indicated the Strategic Trust - Kelly CRISPR & Gene Editing Technology ETF had ceased operations, though shares continued trading into 2025 with a 52-week range of $5.87 to $11.83 and a dividend yield of 0.12%. No major partnerships, acquisitions, or new product launches were reported for the issuer in 2024-2025; instead, related Kelly entities pursued share repurchases and segment shifts, while the ETF's portfolio reflected concentration risks in the volatile biotech theme.